FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975304410> ?p ?o ?g. }

• W1975304410 endingPage "401" @default.
• W1975304410 startingPage "393" @default.
• W1975304410 abstract "Study objectives 18F-fluorodeoxyglucose (FDG) is the most widely used positron emission tomography (PET) imaging probe used for the diagnosis, staging, restaging, and monitoring therapy response of cancer. However, its specificity is less than ideal. A new molecular imaging probe (18F-deoxyfluorothymidine [FLT]) has been developed that might afford more specific tumor imaging. The aims of this study were as follows: (1) to compare the use of FDG-PET and FLT-PET for tumor staging, (2) to compare the degree of FDG and FLT uptake in lung lesions, and (3) to determine the correlation between PET uptake intensity and tumor cell proliferation. Design FDG-PET and FLT-PET scans were performed in 11 patients with solitary pulmonary nodules and another 11 patients with known non-small cell lung cancer (NSCLC). Tracer uptake was assessed quantitatively by standardized uptake values (SUVs). Histologic evaluation of tissue samples obtained from biopsy specimens or surgical resections served as the “gold standard.” Tumor cell proliferation was assessed by Ki-67 staining. Results Pathology verification was available from 99 tissue samples in the 22 patients (29 pulmonary lesions, 66 lymph node stations, and 4 extrapulmonary lesions). Thirty-three samples (33.3%) were positive for tumor tissue (22 pulmonary, 9 lymph node stations, and 2 extrapulmonary). FDG-PET findings were false-positive in three pulmonary lesions, while FLT-PET findings were false-positive in one lesion. There were two false-negative findings by FDG-PET and six false-negative findings by FLT-PET. FDG uptake of the malignant lesions was significantly higher than FLT (maximum SUV, 3.1 ± 2.6 vs 1.6 ± 1.2 [mean ± SD]; p < 0.05). A significant correlation was observed between FLT uptake of pulmonary lesions and Ki-67 labeling index (r = 0.60, p = 0.02) but not for FDG uptake (r = 0.27, p = not significant). Conclusions Compared to FDG-PET, detection of primary and metastatic NSCLC by FLT-PET is limited by the relatively low FLT uptake of the tumor tissue. Thus, FLT-PET is unlikely to provide more accurate staging information or better characterization of pulmonary nodules than FDG-PET. Nevertheless, the correlation between FLT uptake and cellular proliferation suggests that future studies should evaluate the use of FLT-PET for monitoring treatment with cytostatic anticancer drugs. 18F-fluorodeoxyglucose (FDG) is the most widely used positron emission tomography (PET) imaging probe used for the diagnosis, staging, restaging, and monitoring therapy response of cancer. However, its specificity is less than ideal. A new molecular imaging probe (18F-deoxyfluorothymidine [FLT]) has been developed that might afford more specific tumor imaging. The aims of this study were as follows: (1) to compare the use of FDG-PET and FLT-PET for tumor staging, (2) to compare the degree of FDG and FLT uptake in lung lesions, and (3) to determine the correlation between PET uptake intensity and tumor cell proliferation. FDG-PET and FLT-PET scans were performed in 11 patients with solitary pulmonary nodules and another 11 patients with known non-small cell lung cancer (NSCLC). Tracer uptake was assessed quantitatively by standardized uptake values (SUVs). Histologic evaluation of tissue samples obtained from biopsy specimens or surgical resections served as the “gold standard.” Tumor cell proliferation was assessed by Ki-67 staining. Pathology verification was available from 99 tissue samples in the 22 patients (29 pulmonary lesions, 66 lymph node stations, and 4 extrapulmonary lesions). Thirty-three samples (33.3%) were positive for tumor tissue (22 pulmonary, 9 lymph node stations, and 2 extrapulmonary). FDG-PET findings were false-positive in three pulmonary lesions, while FLT-PET findings were false-positive in one lesion. There were two false-negative findings by FDG-PET and six false-negative findings by FLT-PET. FDG uptake of the malignant lesions was significantly higher than FLT (maximum SUV, 3.1 ± 2.6 vs 1.6 ± 1.2 [mean ± SD]; p < 0.05). A significant correlation was observed between FLT uptake of pulmonary lesions and Ki-67 labeling index (r = 0.60, p = 0.02) but not for FDG uptake (r = 0.27, p = not significant). Compared to FDG-PET, detection of primary and metastatic NSCLC by FLT-PET is limited by the relatively low FLT uptake of the tumor tissue. Thus, FLT-PET is unlikely to provide more accurate staging information or better characterization of pulmonary nodules than FDG-PET. Nevertheless, the correlation between FLT uptake and cellular proliferation suggests that future studies should evaluate the use of FLT-PET for monitoring treatment with cytostatic anticancer drugs." @default.
• W1975304410 created "2016-06-24" @default.
• W1975304410 creator A5007642190 @default.
• W1975304410 creator A5048242184 @default.
• W1975304410 creator A5049548593 @default.
• W1975304410 creator A5066257150 @default.
• W1975304410 creator A5068541137 @default.
• W1975304410 creator A5075793654 @default.
• W1975304410 creator A5080877411 @default.
• W1975304410 date "2006-02-01" @default.
• W1975304410 modified "2023-10-10" @default.
• W1975304410 title "Evaluation of Thoracic Tumors With 18F-Fluorothymidine and 18F-Fluorodeoxyglucose-Positron Emission Tomography" @default.
• W1975304410 cites W1489313047 @default.
• W1975304410 cites W1971534487 @default.
• W1975304410 cites W1973296558 @default.
• W1975304410 cites W1979491371 @default.
• W1975304410 cites W1980311256 @default.
• W1975304410 cites W1987444921 @default.
• W1975304410 cites W1987934775 @default.
• W1975304410 cites W1993312546 @default.
• W1975304410 cites W1994827949 @default.
• W1975304410 cites W1995282090 @default.
• W1975304410 cites W1998413486 @default.
• W1975304410 cites W2000926671 @default.
• W1975304410 cites W2018757817 @default.
• W1975304410 cites W2058743530 @default.
• W1975304410 cites W2069752504 @default.
• W1975304410 cites W2085961182 @default.
• W1975304410 cites W2086184737 @default.
• W1975304410 cites W2094129713 @default.
• W1975304410 cites W2118803057 @default.
• W1975304410 cites W2134509758 @default.
• W1975304410 cites W2151523321 @default.
• W1975304410 cites W2166610783 @default.
• W1975304410 doi "https://doi.org/10.1378/chest.129.2.393" @default.
• W1975304410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16478857" @default.
• W1975304410 hasPublicationYear "2006" @default.
• W1975304410 type Work @default.
• W1975304410 sameAs 1975304410 @default.
• W1975304410 citedByCount "158" @default.
• W1975304410 countsByYear W19753044102012 @default.
• W1975304410 countsByYear W19753044102013 @default.
• W1975304410 countsByYear W19753044102014 @default.
• W1975304410 countsByYear W19753044102015 @default.
• W1975304410 countsByYear W19753044102016 @default.
• W1975304410 countsByYear W19753044102017 @default.
• W1975304410 countsByYear W19753044102018 @default.
• W1975304410 countsByYear W19753044102019 @default.
• W1975304410 countsByYear W19753044102020 @default.
• W1975304410 countsByYear W19753044102021 @default.
• W1975304410 countsByYear W19753044102022 @default.
• W1975304410 countsByYear W19753044102023 @default.
• W1975304410 crossrefType "journal-article" @default.
• W1975304410 hasAuthorship W1975304410A5007642190 @default.
• W1975304410 hasAuthorship W1975304410A5048242184 @default.
• W1975304410 hasAuthorship W1975304410A5049548593 @default.
• W1975304410 hasAuthorship W1975304410A5066257150 @default.
• W1975304410 hasAuthorship W1975304410A5068541137 @default.
• W1975304410 hasAuthorship W1975304410A5075793654 @default.
• W1975304410 hasAuthorship W1975304410A5080877411 @default.
• W1975304410 hasConcept C126322002 @default.
• W1975304410 hasConcept C126838900 @default.
• W1975304410 hasConcept C142724271 @default.
• W1975304410 hasConcept C199374082 @default.
• W1975304410 hasConcept C2775842073 @default.
• W1975304410 hasConcept C2775934546 @default.
• W1975304410 hasConcept C2776256026 @default.
• W1975304410 hasConcept C2777415128 @default.
• W1975304410 hasConcept C2777714996 @default.
• W1975304410 hasConcept C2780849966 @default.
• W1975304410 hasConcept C2781156865 @default.
• W1975304410 hasConcept C2989005 @default.
• W1975304410 hasConcept C40993552 @default.
• W1975304410 hasConcept C71924100 @default.
• W1975304410 hasConceptScore W1975304410C126322002 @default.
• W1975304410 hasConceptScore W1975304410C126838900 @default.
• W1975304410 hasConceptScore W1975304410C142724271 @default.
• W1975304410 hasConceptScore W1975304410C199374082 @default.
• W1975304410 hasConceptScore W1975304410C2775842073 @default.
• W1975304410 hasConceptScore W1975304410C2775934546 @default.
• W1975304410 hasConceptScore W1975304410C2776256026 @default.
• W1975304410 hasConceptScore W1975304410C2777415128 @default.
• W1975304410 hasConceptScore W1975304410C2777714996 @default.
• W1975304410 hasConceptScore W1975304410C2780849966 @default.
• W1975304410 hasConceptScore W1975304410C2781156865 @default.
• W1975304410 hasConceptScore W1975304410C2989005 @default.
• W1975304410 hasConceptScore W1975304410C40993552 @default.
• W1975304410 hasConceptScore W1975304410C71924100 @default.
• W1975304410 hasIssue "2" @default.
• W1975304410 hasLocation W19753044101 @default.
• W1975304410 hasOpenAccess W1975304410 @default.
• W1975304410 hasPrimaryLocation W19753044101 @default.
• W1975304410 hasRelatedWork W1990931033 @default.
• W1975304410 hasRelatedWork W2003237182 @default.
• W1975304410 hasRelatedWork W2008460655 @default.
• W1975304410 hasRelatedWork W2041797039 @default.
• W1975304410 hasRelatedWork W2084171621 @default.
• W1975304410 hasRelatedWork W2117290479 @default.

• next